ClearPoint Neuro, Inc.

CLPT Healthcare Medical Devices

ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

9.07 0.57 −5.91%
Market cap
$294.1M
P/E
0.0×
Fwd P/E
−11.6×
Dividend yield
—
F-score
4/9
Altman Z
0.44
Beneish M
−1.74
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
4 4 2 3 4 3 4 4 6 3
P/S ratio
10.48 13.24 6.94 9.79 14.27 19.63 5.63 2.33 2.77 1.63
Altman Z-Score
0.44 11.08 (1.36) 3.17 6.07 0.54 (7.74) (18.02) (8.85) (19.13)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(4.93) (13.52) (11.26) (3.48) 0.74 (9.58) (29.14) (44.72) (22.07) (45.53)
Beneish M-Score
(1.74) (3.24) (2.91) (2.30) (2.35) (1.86) (3.36) (2.99) (2.84) (3.82)
P/Operating CF
(32.07) (334.42) (142.29) (65.64) (65.49) (104.90) (135.41) (29.46) (11.70) (8.43)
P/B ratio
13.82 16.37 7.86 5.45 4.77 105.96 13.77 11.35 3.50 0.00
Price to Tangible BV
58.46 16.44 8.00 5.52 4.82 140.86 15.47 24.20 4.12 0.00
EV/Sales
10.56 12.92 6.40 8.45 11.56 19.73 5.32 2.66 2.18 2.57
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(16.33) (45.32) (11.17) (10.74) (14.84) (32.42) (20.92) (4.22) (2.68) (2.54)
EV/FCF
(15.63) (40.44) (10.22) (10.03) (14.16) (30.50) (19.73) (4.16) (2.67) (2.49)
Quick Ratio
4.87 2.40 3.55 5.92 11.88 6.87 1.77 2.32 2.33 1.39
Current Ratio
5.91 3.22 4.87 7.54 13.02 7.96 2.71 3.56 2.90 2.02
Net Debt/EBITDA
(0.14) 1.13 0.63 1.78 3.52 (0.25) 1.00 (0.08) 0.75 (0.17)
Debt/Assets
50.21% 0.00% 23.32% 17.83% 15.00% 72.09% 17.38% 44.30% 35.39% 60.69%
Debt/Equity
1.75 0.00 0.47 0.27 0.20 8.95 0.45 2.30 0.84 (5.94)
Asset Turnover
0.54 0.77 0.49 0.34 0.34 0.62 1.13 0.68 0.69 0.66
Operating CF/Net income
0.94 0.47 0.62 0.98 0.88 1.15 0.51 0.75 0.84 0.72
Capex/Depreciation
(0.22) (0.14) (0.69) (1.38) (0.21) (0.33) (0.16) (0.09) (0.05) (0.17)
Interest Coverage
(10.12) (38.10) 58.15 (201.63) (13.75) (4.31) (4.81) (5.35) (7.26) (7.12)
ROE
(95.64%) (81.24%) (76.09%) (38.37%) (56.33%) (194.80%) (181.73%) (167.95%) (282.59%) 589.65%
ROA
(37.30%) (46.22%) (45.01%) (27.15%) (30.31%) (32.73%) (56.01%) (56.66%) (67.30%) (93.09%)
ROIC
(48.45%) (233.37%) (175.75%) (109.86%) (185.09%) (109.26%) (298.16%) (173.49%) (271.78%) (1,114.66%)
Return on Tangible Assets
(46.05%) (75.61%) (73.31%) (36.36%) (24.98%) (30.03%) (79.17%) (119.33%) (83.19%) (237.66%)
Average Days of Receivables
64.66 54.80 48.93 47.33 52.33 53.52 35.47 61.25 46.96 54.97
Research and Development Expense of Revenue
37.59% 39.48% 48.88% 53.01% 56.94% 36.53% 25.05% 31.42% 38.13% 45.71%
Selling, General and Administrative Expense of Revenue
89.15% 84.31% 101.65% 92.30% 93.36% 83.05% 80.76% 106.86% 108.45% 138.57%
Intangible Assets out of Total Assets
0.22 0.00 0.01 0.01 0.01 0.02 0.04 0.10 0.06 0.13
Share Based Compensation of Revenue
22.13% 22.00% 25.38% 20.08% 12.75% 8.50% 7.12% 17.80% 23.68% 21.74%
Graham Net Nets
(0.02) 0.05 0.09 0.16 0.19 (0.01) 0.05 0.02 0.23 (0.22)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.43
Earnings Yield
(6.65%) (4.55%) (13.46%) (8.17%) (5.97%) (2.64%) (8.96%) (35.67%) (42.42%) (93.59%)
Free Cash Flow Yield
(6.45%) (2.41%) (9.01%) (8.61%) (5.72%) (3.30%) (4.79%) (27.36%) (29.47%) (63.21%)
Revenue per Share
1.31 1.16 0.97 0.85 0.79 0.81 0.85 0.67 0.95 2.09
Operating CF per Share
(0.84) (0.33) (0.56) (0.67) (0.61) (0.49) (0.22) (0.42) (0.77) (2.11)
Capex per Share
(0.02) (0.01) (0.04) (0.05) (0.01) (0.03) (0.01) (0.01) 0.00 (0.04)
Free Cash Flow per Share
(0.86) (0.34) (0.60) (0.72) (0.62) (0.52) (0.23) (0.43) (0.78) (2.15)
Cash per Share
1.62 0.74 0.94 1.55 2.61 1.27 0.43 0.28 1.20 1.20
Shareholders Equity per Share
0.99 0.94 0.86 1.53 2.35 0.15 0.35 0.14 0.75 (0.27)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.99 0.94 0.86 1.53 2.35 0.15 0.35 0.14 0.75 (0.27)
Free Cash Flow
(24.45) (9.22) (14.77) (17.31) (12.86) (8.29) (3.01) (4.69) (6.02) (5.92)
Working Capital
52.84 23.01 28.74 44.39 57.14 22.26 6.55 4.79 8.35 3.07
Capital Expenditures
(0.52) (0.27) (1.05) (1.15) (0.17) (0.48) (0.16) (0.06) (0.03) (0.10)
Net Current Asset Value
(6.13) 19.56 14.68 32.58 45.10 (1.68) 3.04 0.31 4.68 (2.07)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.01 0.01 0.04 0.06 0.01 0.04 0.01 0.01 0.00 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.89 0.97 1.09 1.03 1.47 4.51 2.19 1.78 2.03 1.77
Cash ROIC
(19.87%) (20.28%) (27.22%) (20.54%) (11.41%) (18.94%) (24.36%) (58.00%) (30.04%) (83.97%)
Accounts Receivable Turnover
6.57 7.92 8.15 8.22 7.73 8.64 9.65 6.74 8.13 5.52
Accounts Payable Turnover
11.00 14.16 31.10 20.09 14.24 5.86 5.37 3.86 2.51 2.35
Inventory Turnover
1.88 1.66 1.20 0.99 1.27 1.15 1.47 1.10 1.42 1.48
Average Days of Payables
32.11 39.87 13.87 14.14 30.11 29.52 89.44 75.14 95.62 213.64
Days of Inventory on Hand
213.67 204.19 279.23 483.70 348.22 318.65 300.00 315.93 291.39 244.24
Average Receivables
5.63 3.96 2.94 2.50 2.11 1.49 1.16 1.09 0.91 1.04
Average Payables
1.30 0.87 0.33 0.35 0.36 0.63 0.73 0.63 1.15 1.12
Average Inventory
7.61 7.39 8.61 7.12 4.09 3.24 2.67 2.21 2.04 1.79
Average Assets
68.47 40.93 49.08 60.54 47.55 20.72 9.89 10.88 10.65 8.67
Average Common Equity
26.70 23.28 29.03 42.84 25.58 3.48 3.05 3.67 2.54 (1.37)

Fold the line items

Columns are period end dates